BioXcel Therapeutics, Inc. cotiza a 0.04 USD y tiene una capitalización bursátil de $1M. En los últimos 12 meses ha facturado $742000 con un margen de flujo de caja libre del -8974.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of a…
| Periodo | 2026-08 | 2026-05 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.49 | $-0.54 | $-2.16 | $-2.45 |
| Estimado | $-0.58 | $-0.48 | $-1.34 | $-1.56 |
| Sorpresa | +15.5% | -12.5% | -61.2% | -57.1% |
| Métrica | BTAIQ | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 74.5% | 57.0% | +17.4% |
| Operating Margin | -7860.0% | -38.6% | -7821.4% |
| Net Margin | -10887.4% | -33.6% | -10853.8% |
| FCF Margin | -8974.3% | -13.9% | -8960.4% |
| ROE | — | -40.4% | — |
| ROA | -155.6% | -32.0% | -123.6% |
| Current Ratio | 0.83 | 2.84 | -2.01 |
| Debt / Equity | -1.15 | 0.28 | -1.43 |